Indoleamine 2,3-dioxygenase is a novel prognostic indicator for endometrial cancer by Ino, K et al.
Indoleamine 2,3-dioxygenase is a novel prognostic indicator for
endometrial cancer
K Ino*,1, N Yoshida
1, H Kajiyama
1, K Shibata
1, E Yamamoto
1, K Kidokoro
1, N Takahashi
1, M Terauchi
1,
A Nawa
1, S Nomura
1, T Nagasaka
2, O Takikawa
3 and F Kikkawa
1
1Department of Obstetrics and Gynecology, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya 466-8550, Japan;
2Division of Pathology/Clinical Laboratory, Nagoya University Graduate School of Medicine, Nagoya, Japan;
3National Institute for Longevity Sciences,
National Center for Geriatrics and Gerontology, Obu, Japan
Indoleamine 2,3-dioxygenase (IDO) is a tryptophan-catabolising enzyme inducing immune tolerance. The present study aimed to
investigate IDO expression and its prognostic significance in endometrial cancer. Indoleamine 2,3-dioxygenase expression in
endometrial cancer tissues (n¼80) was immunohistochemically scored as four groups (IDO ,1þ,2þ, and 3þ). The high IDO
expression (IDO2þ or 3þ) in tumour cells was found in 37 (46.3%) of the 80 cases, and was positively correlated with surgical
stage, myometrial invasion, lymph-vascular space involvement, and lymph node metastasis, but not with the histological grade.
Patients with high IDO expression had significantly impaired overall survival and progression-free survival (PFS) (P¼0.002 and
P¼0.001, respectively) compared to patients with no or weak expression of IDO (IDO  or 1þ). The 5-year PFS for IDO /1þ,
2þ, and 3þ were 97.7, 72.9, and 36.4%, respectively. Even in patients with early-stage disease (International Federation of
Gynecology and Obstetrics I/II, n¼64), the PFS for IDO2þ/3þ was significantly poor (P¼0.001) compared to that for IDO /1þ.
On multivariate analysis, IDO expression was an independent prognostic factor for PFS (P¼0.020). These results indicated that the
high IDO expression was involved in the progression of endometrial cancer and correlated with the impaired clinical outcome,
suggesting that IDO is a novel and reliable prognostic indicator for endometrial cancer.
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Endometrial cancer is the most common malignancy of the female
genital tract (Jemal et al, 2004). In three-fourths of cases of this
disease, the tumour is clinically confined to the uterus at the time
of diagnosis, and most patients with early-staged disease achieve a
favourable clinical outcome with surgery alone (Morrow et al,
1991; Grigsby et al, 1992). However, a significant number of
patients with early-staged disease develop localised recurrence or
distant metastases, and the patients with recurrence or advanced
disease show a poor outcome (Lotocki et al, 1983). Several
clinicopathological parameters are currently used for the classifi-
cation of risks for relapse and death, such as surgical stage,
histological type, grade, depth of myometrial invasion, cervical
stromal invasion, lymph node metastasis, lymph-vascular involve-
ment, and peritoneal cytology (Morrow et al, 1991; Grigsby et al,
1992). For patients belonging to high or intermediate risk groups
defined by these parameters, either postoperative adjuvant
radiation therapy, or chemotherapy has been used (Creutzberg
et al, 2000; Keys et al, 2004; Sagae et al, 2005). However, selecting
the patients that will receive the adjuvant therapy, and its
effectiveness, especially its impact on survival remain controversial
(Cardenes and Randall, 2003). Thus, in addition to the conven-
tional clinicopathological parameters, the identification of bio-
chemical or molecular markers more strictly related to the
intrinsic biological behaviour of endometrial cancer, and the
individualisation of adjuvant therapy based on more reliable
prognostic indicators, may be helpful in further improving the
survival of patients with this disease, as well as in preventing the
unnecessary use of adjuvant therapy.
Indoleamine 2,3-dioxygenase (IDO; EC 1.13.11.42) is a haeme-
containing intracellular enzyme that catalyses the initial and rate-
limiting steps in the metabolism of the essential amino acid
tryptophan along the kynurenine pathway (Takikawa et al, 1986).
Recently, evidence for an immunosuppressive function of IDO has
been accumulating. Indoleamine 2,3-dioxygenase is expressed in
placental cells during pregnancy and prevents rejection of the
allogeneic foetus by depleting tryptophan locally and producing
tryptophan metabolites, which causes the apoptosis of maternal
alloreactive T cells or natural killer cells that are extremely
sensitive to tryptophan shortage (Munn et al, 1998). Indoleamine
2,3-dioxygenase is also expressed in certain types of activated
macrophages or dendritic cells, and regulates the immune
response and induces tolerance (Mellor and Munn, 2004).
In malignancy, Uyttenhove et al (2003) demonstrated for the
first time that IDO was expressed in various human cancer tissues,
and that IDO was involved in protecting tumours from attack by
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stumour-associated antigen-specific host cytotoxic T cells. Further-
more, it has been reported that IDO was expressed not only by
tumour cells themselves, but also by dendritic cells in tumour-
draining lymph nodes, and that melanoma patients with IDO-
positive cells in lymph nodes had a poor clinical outcome (Munn
et al, 2004). More recently, it was shown that IDO inhibitors
potentiated the antitumour activity of chemotherapeutic agents in
mice, suggesting the involvement of IDO in the refractoriness to
chemotherapy (Muller et al, 2005), consistent with another report
showing that IDO was associated with chemoresistance in ovarian
cancer (Okamoto et al, 2005). Based on the above findings,
considerable attention is now being paid to the functional role of
IDO in the progression of human cancer and its therapeutic
potential as a new prognostic marker or a molecular target.
However, there have been few studies on IDO expression in a large
number of human tumour samples (Brandacher et al, 2006), and
its prognostic significance has not yet been well studied.
In the current study, we performed immunohistochemical
analysis for IDO expression in a total of 80 tissue samples of
endometrial cancer, and demonstrated that high IDO expression
was a reliable indicator for disease progression and the poor
prognosis of endometrial cancer.
MATERIALS AND METHODS
Reagents and antibodies
Mouse monoclonal antibody against human IDO was prepared
as described previously (Takikawa et al, 1988). L-tryptophan,
catalase, ascorbic acid, methylene blue, L-kynurenine, and
dimethylaminobenzaldehyde were all purchased from Sigma
Chemical Co. (St Louis, MO, USA).
Immunoblot analysis
Tumour tissue samples were homogenised in a lysis buffer
consisting of 1% Triton X-100 and the protease inhibitor mixture
in phosphate-buffered saline. After centrifugation at 15000g for
20min, the supernatant was obtained. Thirty micrograms of
protein extract was separated by SDS/10% polyacrylamide gel
electrophoresis, transferred onto the nitrocellulose membrane, and
immunoblotted with anti-IDO monoclonal antibody at a dilution
of 1:1000. Immunoreactive proteins were stained using a
chemiluminescence detection system (ECL, Amersham, Arlington
Heights, IL, USA).
Assay for IDO enzymatic activity
IDO enzymatic activity was determined colorimetrically according
to the previous reports (Kudo and Boyd, 2000) with minor
modifications. Briefly, 0.1ml of protein extract was mixed with
0.1ml of the substrate solution composed of 10mML -tryptophan,
10mgml
 1 catalase, 200mM ascorbic acid, 500mM methylene blue,
and 500mM potassium phosphate buffer (pH 6.5), and incubated at
371C for 60min. The reaction was terminated by the addition of
40ml of 30% trichloroacetic acid and further incubated at 501C for
15min to hydrolyse N-formylkynurenine produced by IDO to
kynurenine. After centrifugation for 20min at 3000g, 0.1ml of the
supernatant was collected, and then 0.1ml of 2% dimethylamino-
benzaldehyde in acetic acid was added. As the standard assay,
0.1ml of 100mML -kynurenine was mixed with dimethylamino-
benzaldehyde. The absorbance at 480nm for the yellow colour
derived from kynurenine was determined.
Patients and case selection
Eighty patients with endometrial endometrioid adenocarcinoma
who underwent surgical treatment at Nagoya University Hospital
between 1992 and 2001 were included in this study. Initial
diagnoses were made preoperatively by the pathological review
of endometrial biopsy or curettage specimens. Surgical treatment
consisted of total abdominal hysterectomy and bilateral salpingo-
oophorectomy, followed by surgical staging, including peritoneal
washing cytology and lymphadenectomy. Patients with the
histological cell types other than endometrioid adenocarcinoma,
such as papillary serous or clear cell, were not included in this
study. The mean age of the patients was 57.2 years (range 31–86).
All patients were staged according to the 1988 International
Federation of Gynecology and Obstetrics (FIGO) criteria: 54 were
stage I (seven were IA, 33 were IB, 14 were IC), 10 were stage II, 10
were stage III and six were stage IV. Histological grade was
assigned according to the criteria of the World Health Organiza-
tion (WHO) classification: 40 were G1 (well differentiated), 27 were
G2 (moderately differentiated), and 13 were G3 (poorly differ-
entiated). In this study, all patients with FIGO stage IC and more
advanced-staged disease received postoperative adjuvant chemo-
therapy with six cycles of either cisplatin/doxorubicin/cyclo
phosphamide or cisplatin plus etoposide in 1992–1999, and
carboplatin plus paclitaxel after 2000. Patients receiving post-
operative radiation therapy or any preoperative treatment were
excluded from this study because the number of these patients was
very small. Tumour recurrence/progression was defined based on
clinical, radiological or histological diagnosis. Patients with
recurrence were treated with the chemotherapy, local radiation
therapy, or surgical tumour resection if possible.
Immunohistochemistry
Informed consent was obtained from individual patients for the
use of their tissue samples. Surgical specimens were fixed in 10%
formalin and embedded in paraffin. Paraffin specimens were cut
at a thickness of 4mm. For heat-induced epitope retrieval,
deparaffinised sections were soaked in Target Retrieval Solution
consisting of 10mM Tris and 1mM EDTA (DAKO, Glostrup,
Denmark), and treated at 951C for 30min in a microwave oven.
Immunohistochemical staining was performed using the avidin–
biotin immunoperoxidase technique. Endogenous peroxidase
activity was blocked by incubation with 0.3% H2O2 in methanol
for 15min, and nonspecific immunoglobulin binding was blocked
by incubation with 10% normal goat serum for 10min. Sections
were incubated at room temperature for 2h with anti-IDO
monoclonal antibody at 1:200 dilution. The sections were rinsed
and incubated for 30min with the biotinylated second antibody.
After washing, the sections were incubated for 30min with
horseradish peroxidase-conjugated streptavidin, and finally trea-
ted with 3,30-diaminobenzidine tetrahydrochloride in 0.01% H2O2
for 10min. The slides were counterstained with Meyer’s hemato-
xylin. As a negative control, the primary antibody was replaced
with normal mouse IgG at an appropriate dilution. As a positive
control, tissue sections of normal placenta were used as previously
reported (Sedlmayr et al, 2002).
The IDO expression levels were classified semiquantitatively
based on the total scores of the percent positivity of stained
tumour cells and the staining intensity. Namely, the percent
positivity was scored as ‘0’ if o5% (negative), ‘1’ if 5–30%
(sporadic), ‘2’ if 30–70% (focal), and ‘3’ if 470% (diffuse) of cells
stained, whereas the staining intensity was scored relative to the
known positive and negative controls as ‘0’ if no staining, ‘1’ if
weakly stained, ‘2’ if moderately stained (intermediate level
between strong and weak), and ‘3’ if strongly stained. The final
IDO expression score was defined as follows; ‘IDO ’ if the sum of
the percent positivity score and the staining intensity score was
0–1, ‘IDO1þ’ if the sum was 2–3, ‘IDO2þ’ if the sum was 4–5,
and ‘IDO3þ’ if the sum was 6. In this scoring system, IDO
expression in the tumour stromal cells was not considered because
the IDO immunostaining in non-tumour cells was not remarkable
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sor absent, whereas it was dominant in tumour cells, in all cases
examined. In each case, at least three different areas were
evaluated, and the mean of the results was considered the final
expression score. The scoring procedure was carried out twice by
two independent observers (each blinded to the other’s score)
without any knowledge of the clinical data. The concordance rate
was over 95% between the observers. In the case of disagreement,
the slides were reviewed simultaneously by these two observers,
with another, different observer, who were seated together at a
multiheaded microscope, in order to resolve the difference of
opinion.
Statistical analysis
Fisher’s exact test and Pearson w
2 test were used to analyse the
correlation of IDO expression with various clinicopathological
parameters. Overall survival (OS) was calculated from the date of
surgery to the date of death, and progression-free survival (PFS)
was calculated from the date of surgery to the date of progression/
recurrence or date of last follow-up. Survival analyses were
performed according to the Kaplan–Meier method. Comparison
of the survival between groups was performed with the log-rank
test. Cox proportional-hazard analysis was used for univariate and
multivariate analysis to explore the effect of variables on survival.
The SAS software (SAS Institute Inc., Cary, NC, USA) was used for
all statistical analyses, and a P-value of o0.05 was considered
significant.
RESULTS
IDO protein expression and enzyme activity in
endometrial cancer tissues
First, the IDO protein expression was examined in the endometrial
cancer tissues obtained from seven patients using Western blot
analysis. In all samples, IDO protein was detected as approximately
42kDa bands, although its expression level varied among the
samples (Figure 1A). To confirm whether IDO expressed in these
tissues is enzymatically active, the IDO activity was measured by
assessing the degradation of tryptophan to generate kynurenine.
The IDO enzyme activity was confirmed in all samples and
corresponded to the protein expression level (Figure 1B).
Immunohistochemical expression of IDO in endometrial
cancer tissues
We examined the IDO expression in endometrial cancer by
immunohistochemical staining, using a total of 80 surgical
specimens. As shown in Figure 2A–F, the immunoreactivity of
IDO was detected at variable levels, and was localised in the
cytoplasm of tumour cells. In contrast, the immunoreactivity of
IDO was very faint or absent in the tumour stroma. Of the 80
specimens examined, the ‘high IDO expression’ (IDO2þ or 3þ)
were found in 37 (46%) cases, of which 25 (31%) were IDO2þ and
12 (15%) were IDO3þ, IDO , and IDO1þ tumours were found
in 15 (19%) and 28 (35%) cases, respectively. The IDO
immunoreactivity was not detected in the negative control
experiments (Figure 2G), whereas it was strongly detected in the
placental tissues used as a positive control (Figure 2H).
The correlation of the high IDO expression (IDO2þ and 3þ)
with various clinicopathological parameters in the 80 cases are
summarised in Table 1. The high IDO expression was positively
correlated with the FIGO stage (P¼0.001), myometrial invasion
(P¼0.001), lymph-vascular space involvement (P¼0.001) and
lymph node metastasis (P¼0.023), but not with the histological
grade.
Correlation of IDO expression with the patient survival
Follow-up data were available for all 80 patients. The median
follow-up period was 71.6 months (range 5–148). During the
follow-up period, disease progression/recurrence was observed in
14 cases (17.5%), in which nine patients (11.3%) died. The median
time to progression/recurrence and death were 10.5 and 17.8
months, respectively.
To evaluate the impact of IDO expression on patient prognosis,
OS, and PFS curves were constructed using the Kaplan–Meier
method. The OS rates of patients with IDO /1þ, IDO2þ, and
IDO3þ were 96.8, 82.5, and 63.6%, respectively (Figure 3A). The
5-year PFS rates for IDO /1þ, IDO2þ, and IDO3þ were 97.7,
72.9, and 36.4%, respectively (Figure 3B). Patients with high IDO
expression (IDO2þ or 3þ) had significantly impaired OS
(P¼0.002) and PFS (P¼0.001) as compared to patients with no
or weak expression of IDO (IDO  or 1þ) (Figure 3A and B).
Next, we analysed the correlation of IDO expression with PFS in
the patients with early-staged disease. In FIGO stage I/II patients
(n¼64), the 5-year PFS rates for IDO /1þ and IDO2þ/3þ were
100 and 75.0%, respectively, and there was a significant difference
in the PFS between the two groups (P¼0.001) (Figure 3C). Finally,
we analysed the correlation of IDO expression with PFS in the
patients with FIGO stage Ic and greater (Ic-IV, n¼40), because all
these patients underwent postoperative adjuvant chemotherapy
owing to the risk of disease recurrence/progression. In these
patients, the 5-year PFS rates for IDO /1þ and IDO2þ/3þ were
92.9 and 58.8%, respectively, with a marked difference between the
two groups (P¼0.027) (Figure 3D).
Multivariate analysis of prognostic variables in
endometrial cancer patients
Cox proportional-hazard analysis was performed to compare the
impact of IDO expression on survival with those of currently used
clinicopathological prognostic factors. The results of the uni-
variate/multivariate analyses of the variables, including IDO
expression, age, FIGO stage, grade, myometrial invasion, and
lymph-vascular space involvement, with respect to OS and PFS are
shown in Tables 2 and 3, respectively. Among the six variables, the
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Figure 1 Indoleamine 2,3-dioxygenase expression in endometrial cancer
tissues according to Western blot analysis (A) and enzyme activity assay
(B). Lane 1–7 corresponded to the seven different endometrial cancer
patients (G1, grade 1; G2, grade 2; and G3, grade 3). P, placental tissue used
as a positive control.
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sFIGO stage was the only significant prognostic factor (hazard
ratio¼5.59, P¼0.021) with respect to OS on multivariate analysis,
although IDO expression, as well as stage, myometrial invasion,
and lymph-vascular space involvement, were significant prognostic
factors on univariate analysis (Table 2). In contrast, both IDO
expression (hazard ratio¼12.04, P¼0.020) and FIGO stage
(hazard ratio¼4.52, P¼0.009) were found to be independent
prognostic factors with respect to PFS on multivariate analysis
(Table 3).
DISCUSSION
In the present study, we demonstrated the expression of the
tryptophan-catabolising and immunosuppressive enzyme, IDO, in
endometrial cancer using 80 surgical specimens, and found that
the high IDO expression by tumour cells was positively correlated
with disease progression and the impaired patient survival. This
is the first study to demonstrate the detailed clinicopathological
and prognostic impact of IDO expression in human cancer using a
large number of clinical samples.
Prior studies showed that IDO was barely expressed in the
proliferative phase of the normal endometrium, whereas its
expression was increased in the secretory phase, suggesting that
IDO expression in the normal endometrium is physiologically
regulated, dependent on the menstrual cycle (Sedlmayr et al, 2002;
Kudo et al, 2004). In contrast, the present study showed that the
frequency of IDO expression in endometrial cancer was high.
Indeed, IDO was highly expressed in 37 out of 80 (46%) cases,
whereas IDO-negative tumours were found in only 15 (19%) cases.
Several studies showed that IDO was localised in tumour cells, as
well as in some macrophages and eosinophil granulocytes in the
tumour stroma, or in dendritic cells in tumour-draining lymph
nodes (Friberg et al, 2002; Munn et al, 2004; Astigiano et al, 2005).
In our study, the localisation of IDO was dominant in tumour cells,
and the IDO expression in the tumour stroma was not prominent
or was absent. Consistently, Uyttenhove et al (2003) showed that
IDO was expressed in the cancer cell itself, in a variety of human
tumour types. In gynaecological malignancies, IDO expression was
detected in cervical, endometrial, and ovarian cancers with a high
rate of positivity, although a very limited number of samples were
analysed in prior studies (Sedlmayr et al, 2003; Uyttenhove et al,
2003). Recently, Okamoto et al (2005) reported that IDO was
expressed in 17 out of 24 cases with advanced ovarian carcinoma.
ABCD
EFGH
Figure 2 Representative immunohistochemical staining for IDO expression in endometrial cancer tissues. (A) IDO  (negative); (B) IDO1þ (sporadic/
weak); (C) IDO2þ (focal/moderate); (D–F) IDO3þ (diffuse/strong); (G) negative control; (H) positive control (normal placenta). Original magnification,
 100 in A–H.
Table 1 Correlation of IDO expression with clinicopathological factors
in endometrial cancer
Patients High IDO expression
Characteristics No. % No. % P-value
All cases 80 100 37 46.3
Age (years)
460 51 63.8 23 45.1 0.819
X60 29 36.3 14 48.3
FIGO stage
I–II 64 80.0 24 37.5 0.001
III–IV 16 20.0 13 81.3
Histological grade
G1 40 50.0 13 32.5
G2 27 33.8 17 63.0 0.118
G3 13 16.3 7 53.8
Myometrial invasion
None 7 8.8 1 14.3
Inner half 44 55.0 15 34.1 0.001
Outer half 29 36.3 21 72.4
Lymph-vascular space involvement
Yes 30 37.5 23 76.7 0.001
No 50 62.5 14 28.0
Lymph node metastasis
Yes 6 7.5 6 100.0 0.023
No 74 92.5 31 41.9
FIGO¼International Federation of Gynecology and Obstetrics; IDO¼indoleamine
2,3-dioxygenase.
IDO expression in endometrial cancer
K Ino et al
1558
British Journal of Cancer (2006) 95(11), 1555–1561 & 2006 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
sSchroecksnadel et al (2005) also showed that the serum tryptophan
concentration was lower in 20 patients with gynaecological cancer,
suggesting the presence of tumour-mediated IDO activity in these
patients. Taken together with our results, IDO is frequently
expressed in gynaecological cancers.
We analysed the correlation of IDO expression with the
clinicopathological parameters in endometrial cancer. The high
IDO expression was significantly correlated with the advanced
stage, the depth of myometrial invasion, the presence of lymph-
vascular space involvement, and lymph node metastasis, but not
with the histological grade. Consistently, Brandacher et al (2006)
showed that the high IDO expression in colorectal cancer was
correlated with the disease stage and liver metastasis, but not with
tumour differentiation. These results suggest that the high IDO
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Figure 3 Overall survival and PFS curves drawn using the Kaplan–Meier method according to the IDO expression in endometrial cancer patients. (A and
B) OS and PFS in all patients (n¼80). Significant differences in the OS (P¼0.002) and PFS (P¼0.001) according to the IDO expression among the three
groups. (C) PFS in stage I–II patients (n¼64). Significant difference between the two groups (P¼0.001). (D) PFS in stage Ic-IV patients (n¼40). Significant
difference between the two groups (P¼0.027).
Table 2 Univariate and multivariate analyses of OS in endometrial cancer patients
Univariate analysis Multivariate analysis
Variables Categories HR
a 95% CI
b P-value HR
a 95% CI
b P-value
Age 460 years 0.24 0.03–1.88 0.173 — — —
X60 years
FIGO stage I/II 10.51 2.61–42.30 0.001 5.59 1.30–23.99 0.021
III/IV
IDO expression 0/1+ 12.47 1.55–100.49 0.018 6.64 0.75–59.14 0.089
2+/3+
Histological grade 1 or 2 2.89 0.72–11.55 0.134 — — —
3
Myometrial invasion None/inner half 4.09 1.02–16.37 0.047 — — —
Outer half
Lymph-vascular space involvement Yes 6.86 1.42–33.08 0.016 — — —
No
OS¼overall survival.
aHR¼hazard ratio.
bCI¼confidence interval
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sexpression is associated with the disease progression of endome-
trial cancer, and it might reflect the local tumour aggressiveness
rather than the grade of tumour differentiation.
The present data clearly demonstrated that the patients with
high IDO expression had an impaired clinical outcome by
analysing the rates of both OS and PFS. Surprisingly, of the
43 patients with no or weak IDO expression, only one
patient developed disease progression/recurrence, whereas 13 out
of the 37 patients with high IDO expression recurred. Consistently,
three recent reports showed the correlation between the high
IDO expression and poor patient prognosis in ovarian cancer, lung
cancer, and colorectal cancer (Astigiano et al, 2005; Okamoto et al,
2005; Brandacher et al, 2006), although they only analysed
the OS. More importantly, our analysis, focusing on the cases
with early-staged disease (FIGO I/II), showed that the patients
with no or weak expression of IDO achieved 100% PFS, whereas
five out of 24 patients with the high IDO expression developed
recurrence (PFS¼75%), and three out of the five recurred
cases were FIGO stage 1B. These findings suggested that the
patients with high IDO expression are very likely to recur and
have poor prognosis, even in cases with early-staged disease at the
time of surgery. Furthermore, our multivariate analysis
demonstrated that only IDO expression, except for the stage, was
an independent prognostic factor for PFS, suggesting that IDO may
be a more reliable prognostic parameter of endometrial cancer
than the currently used clinicopathological factors. Because over
70% of endometrial cancer patients present early-staged disease,
and most of them are curable with surgery alone, it would
be of substantial benefit to define the minority of patients who
are likely to recur, and also to give aggressive adjuvant therapy
to these patients alone. There have been several molecular
markers identified showing the prognostic impact in endometrial
cancer (Mell et al, 2004; Shibata et al, 2004; Stefansson et al, 2004;
Ferguson et al, 2005); however, their clinical application
instead of, or in addition to, the currently used prognostic
factors has not yet been realised. Our data suggests that IDO may
become a useful indicator for the prognosis of endometrial
cancer and may contribute to the individualisation of the
application of adjuvant therapy, not only in advanced staged, but
also in early staged patients. Furthermore, it might contribute to
the cost–benefit by preventing the unnecessary use of adjuvant
therapy.
The mechanism by which IDO expression contributes to the
tumour progression of endometrial cancer remains to be
determined. Recent reports proposed a mechanism that IDO can
induce the growth inhibition of tumour antigen-specific cytotoxic
T cells by depleting the tumour microenvironment of tryptophan
and/or by generating toxic tryptophan metabolites, which causes
the tumour to escape from the host immune systems, leading to
the uncontrolled tumour progression (Uyttenhove et al, 2003;
Munn et al, 2004). Thus, the correlation of the high IDO expression
with disease progression and the impaired patient survival shown
by the present study may be attributable to the immune
suppression by the tumour-mediated IDO activity. This may be
supported by one recent report showing the association of high
IDO expression with a reduction of CD3þ lymphocytes in
colorectal cancer (Brandacher et al, 2006). Another possible
mechanism by which IDO contributes to cancer progression was
proposed by Muller et al (2005), who demonstrated the involve-
ment of IDO in a chemoresistance in cancer. Consistently,
Okamoto et al (2005) showed that IDO was overexpressed in
paclitaxel-resistant ovarian cancer cell lines and tissues using a
gene expression profiling study. Our results demonstrated that
there was a marked difference (92.9 vs 58.8%) in PFS between the
no or low IDO expression group and the high IDO expression
group when focusing on the 40 patients with FIGO stage Ic and
more who underwent postoperative chemotherapy. This might
be due, at least in part, to the resistance of IDO-overexpressing
endometrial cancer cells to chemotherapy. However, to identify the
functional roles of IDO in cancer cells besides its enzymatic or
immunosuppressive actions, further studies are needed.
In conclusion, we demonstrated here that high IDO expression
correlated with the disease progression and impaired clinical
outcome in endometrial cancer patients. Furthermore, IDO was an
independent prognostic factor for PFS. These results indicate that
IDO is a reliable and promising prognostic indicator and may
become a novel molecular target in the strategy for the treatment
of endometrial cancer.
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Table 3 Univariate and multivariate analyses of PFS in endometrial cancer patients
Univariate analysis Multivariate analysis
Variables Categories HR 95% CI P-value HR 95% CI P-value
Age 460 years 0.30 0.07–1.32 0.110 — — —
X60 years
FIGO stage I/II 9.33 3.11–28.01 0.001 4.52 1.46–13.96 0.009
III/IV
IDO expression 0/1+ 20.51 2.68–157.13 0.004 12.04 1.48–97.79 0.020
2+/3+
Histological grade 1 or 2 1.58 0.44–5.66 0.484 — — —
3
Myometrial invasion None/inner half 2.68 0.93–7.75 0.068 — — —
Outer half
Lymph-vascular space involvement Yes 3.55 1.19–10.60 0.023 — — —
No
HR¼hazard ratio; CI¼confidence interval; PFS¼progression-free survival.
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